April 24, 2019
MMRF Launches Fund to Invest in Innovative Firms for Multiple Myeloma Research
News
The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and ... Read more
April 22, 2019
Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
News
Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple ... Read more
April 17, 2019
Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients
News
Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as ... Read more
April 15, 2019
MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
News
The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of ... Read more
April 12, 2019
Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan
News
Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment ... Read more
April 10, 2019April 22, 2019
Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
News
Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of ... Read more
April 8, 2019
GSK Compound Showing Durable Response Rates in Advanced Multiple Myeloma, New Phase 1 Trial Data Find
News
New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year ... Read more
April 5, 2019
OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma
News
OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in ... Read more
April 3, 2019
European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
News
The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and ... Read more
April 1, 2019
FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
News
The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor ... Read more
March 29, 2019March 29, 2019
FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
News
An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat newly ... Read more
March 27, 2019
FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials
News
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after ... Read more

$Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show$

April 24, 2019

MMRF Launches Fund to Invest in Innovative Firms for Multiple Myeloma Research

News

The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the multiple myeloma field and to advance ... Read more

April 22, 2019

Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment

News

Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients — at several sites in the U.S. The ... Read more

April 17, 2019

Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients

News

Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for multiple myeloma patients who received an ... Read more

April 15, 2019

MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients

News

The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The ... Read more

April 12, 2019

Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan

News

Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell ... Read more

$Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show$

April 10, 2019April 22, 2019

Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show

News

Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. ... Read more

April 8, 2019

GSK Compound Showing Durable Response Rates in Advanced Multiple Myeloma, New Phase 1 Trial Data Find

News

New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in patients with relapsed or refractory ... Read more

April 5, 2019

OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma

News

OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the Institute for Myeloma and Bone Cancer ... Read more

April 3, 2019

European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients

News

The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and Pomalyst (pomalidomide, marketed as Imnovid in Europe) as combination therapies ... Read more

April 1, 2019

FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma

News

The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone for patients with multiple myeloma who ... Read more